

## Research Articles

## Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression

Vincenzo Oliva<sup>a,b,c,d</sup>, Alfonso Martone<sup>a</sup>, Giuseppe Fanelli<sup>a,e</sup>, Katharina Domschke<sup>f</sup>, Alessandra Minelli<sup>g,h</sup>, Massimo Gennarelli<sup>g,h</sup>, Paolo Martini<sup>g</sup>, Marco Bortolomasi<sup>i</sup>, Eduard Maron<sup>j,k,l</sup>, Alessio Squassina<sup>m</sup>, Claudia Pisanu<sup>m</sup>, Siegfried Kasper<sup>n,o</sup>, Joseph Zohar<sup>p,q</sup>, Daniel Souery<sup>r</sup>, Stuart Montgomery<sup>s</sup>, Diego Albani<sup>t</sup>, Gianluigi Forloni<sup>t</sup>, Panagiotis Ferentinos<sup>u</sup>, Dan Rujescu<sup>n</sup>, Julien Mendlewicz<sup>v</sup>, Diana De Ronchi<sup>a</sup>, Bernhard T. Baune<sup>w,x,y</sup>, European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network, Alessandro Serretti<sup>z,\*</sup>, Chiara Fabbri<sup>a</sup>

<sup>a</sup> Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

<sup>b</sup> Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), c. Casanova, 143, 08036, Barcelona, Spain

<sup>c</sup> Bipolar and Depressive Disorders Unit, Hospital Clínic de Barcelona. c. Villarreal, 170, 08036, Barcelona, Spain

<sup>d</sup> Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), c. Villarreal, 170, 08036, Barcelona, Spain

<sup>e</sup> Department of Human Genetics, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands

<sup>f</sup> Department of Psychiatry and Psychotherapy, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

<sup>g</sup> Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

<sup>h</sup> Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

<sup>i</sup> Psychiatric Hospital “Villa Santa Chiara”, Verona, Italy

<sup>j</sup> Department of Psychiatry, University of Tartu, Tartu, Estonia

<sup>k</sup> DocuMentalCare Clinic, Tallinn, Estonia

<sup>l</sup> Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, London, United Kingdom

<sup>m</sup> Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy

<sup>n</sup> Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Austria

<sup>o</sup> Department Molecular Neuroscience, Center of Brain Research, Medical University Vienna, Vienna, Austria

<sup>p</sup> Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel

<sup>q</sup> Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel

<sup>r</sup> PsyPluriel - Epsilon Caring for Mental Health Brussels, Brussels, Belgium

<sup>s</sup> Imperial College School of Medicine, London, United Kingdom

<sup>t</sup> Laboratory of Biology of Neurodegenerative Disorders, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

<sup>u</sup> Department of Psychiatry, Athens University Medical School, Athens, Greece

<sup>v</sup> Université Libre de Bruxelles, Brussels, Belgium

<sup>w</sup> Department of Psychiatry and Psychotherapy, University of Münster, Münster, Germany

<sup>x</sup> Department of Psychiatry, Melbourne Medical School, University of Melbourne, Parkville, VIC, Australia

<sup>y</sup> The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia

<sup>z</sup> Department of Medicine and Surgery, Kore University of Enna, Enna, Italy

## ARTICLE INFO

Handling Editor: Prof. A. Meyer-Lindenberg

## Keywords:

Major depression  
Subcortical brain volumes  
Polygenic scores  
Treatment response  
Basal ganglia  
Striatum

## ABSTRACT

A significant proportion of patients with major depressive disorder (MDD) do not experience remission after one or more pharmacological treatments. Research has explored brain structural measures, particularly hippocampal volume, as potential predictors of treatment response, as well as genetic factors.

This study investigated the association of polygenic scores (PGSs) for seven subcortical brain volumes (including the hippocampus, nucleus accumbens, amygdala, and caudate nucleus) with treatment non-response and non-remission in MDD.

Patients with MDD were recruited in the context of five clinical studies, including a total of 3637 individuals. PGSs were estimated using a Bayesian framework and continuous shrinkage priors (PRS-CS-auto) after standard

\* Corresponding author. Department of Medicine and Surgery, Kore University of Enna, Piazza dell'Università, Enna, 94100, Italy.

E-mail address: [alessandro.serretti@icloud.com](mailto:alessandro.serretti@icloud.com) (A. Serretti).

<https://doi.org/10.1016/j.nsa.2024.103937>

Available online 22 January 2024

2772-4085/© 2024 The Author(s). Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

genotype quality control and imputation. Logistic regressions were performed between PGSs and non-response or non-remission in each sample, adjusting for age, sex, baseline symptom severity, recruitment sites, and population stratification. Results were meta-analysed across samples, using a random-effect model.

No association was significant in the meta-analysis after Bonferroni correction. The top finding was found for the caudate volume PGS and non-remission (OR = 1.09, 95% CI = 1.01–1.19,  $p = 0.036$ ), with no evidence of heterogeneity. Leave-one-out sensitivity analyses showed that this result was influenced by the two largest samples in the meta-analysis.

This result should be considered as preliminary as it did not reach the Bonferroni-adjusted significance threshold. Future studies with greater statistical power may enhance the predictive performance of PGSs and contribute to the identification of polygenic predictors of treatment outcomes in MDD, contributing to precision psychiatry.

## 1. Introduction

Major depressive disorder (MDD) is a prevalent psychiatric condition and one of the leading causes of disability worldwide, with a 61.1% increase in the number of disability-adjusted life years (DALYs) over the past two decades (Vos et al., 2020).

Depending on the severity of depression and individual preferences, patients may be prescribed psychotherapeutic or pharmacological treatments, or their combination (Kendrick et al., 2022). The first prescribed medication for depression may fail to produce symptom remission in up to 60% of patients, leading to therapy changes that follow a trial and error approach (e.g., switch to another drug, or augmentation with a different pharmacological agent) (De Carlo et al., 2016; van Westrhenen and Ingelman-Sundberg, 2021). Patients without adequate medication response have higher relapse rates (Rush et al., 2006). Identifying the most suitable treatment for each patient early on, in line with the principles of precision psychiatry (Fusar-Poli et al., 2022; Zanardi et al., 2021), may reduce the burden of the disease and the related costs to society (Serretti, 2022).

Several socio-demographic and clinical factors have been recognised as important predictors of response and remission to psychopharmacological treatment in MDD, such as longer duration of depressive episodes, greater baseline severity, older age, and the presence of anxiety symptoms (Kautzky et al., 2017; Olgiati et al., 2022; Domschke et al., 2010).

Common genetic variants were demonstrated to explain at least 13% of the variability in remission (Pain et al., 2022), therefore polygenic scores (PGSs) represent a promising opportunity for investigating the genetic factors involved in treatment efficacy in MDD (Choi and O'Reilly, 2019). PGSs, alternatively called polygenic risk scores (PRSs), are estimates of an individual's genetic predisposition to a trait or disease based on common genetic polymorphisms across the genome. These scores are calculated according to the individual's genotype profile and relevant data from genome-wide association studies (GWAS) (Craig et al., 2020). PGSs have been employed to understand disease pathogenesis (Fabbri et al., 2020), to identify the genetic overlap between different traits (Oliva et al., 2023; Fanelli et al., 2022a), and are promising potential predictors of treatment outcome (Natarajan et al., 2017). Higher PRSs for MDD, schizophrenia, and attention-deficit hyperactivity disorder were associated with a worse response to medications for depression (Fanelli et al., 2022b; Fabbri et al., 2021a). Interestingly, a low PRS for schizophrenia may decrease the benefits of augmentation with medications commonly employed as first-line treatments for schizophrenia (Fanelli et al., 2021). PGSs for conscientiousness and neuroticism were other factors associated with response, while the PGSs for openness was inversely associated with remission and response (Amare et al., 2018). PGSs for nonpsychiatric phenotypes, including PRSs for coronary artery disease, obesity, and cardioembolic stroke, were also inversely associated with response to treatment (Amare et al., 2019; Marshe et al., 2021).

The prediction of treatment response may be improved by considering PGSs for brain-related traits other than those expressing disease risk. Brain structural measures have been investigated as predictors of

response to treatments in MDD. Alterations in the volumes of subcortical brain structures, particularly the hippocampus, have been among the most replicated findings (Perلمان et al., 2019). Patients with MDD showed a volumetric reduction of the hippocampus compared to healthy controls (Dusi et al., 2015), and the hippocampal volume may distinguish treatment responders from non-responders (Chi et al., 2015). The integrity of white matter tracts in the cortico-striatal-limbic systems was also useful in predicting response to treatment (Perلمان et al., 2019); these tracts connect the orbitofrontal cortex with subcortical structures, such as the nucleus accumbens, amygdala, caudate nucleus, globus pallidus, putamen, and thalamus (Fettes et al., 2017). The importance of subcortical structures in the modulation of response to medications for depression was also highlighted by functional studies showing that the activity of the amygdala may predict response to psychedelic drugs (Kuburi et al., 2022).

Genetic studies in family cohorts and twin studies have revealed varying levels of heritability for the volume of each subcortical structure, ranging from moderate to high. Heritability estimates based on single nucleotide polymorphisms (SNPs) were lower compared to those based on genetic studies in family cohorts and twin studies, as expected. These estimates range from 17% to 47% for the thalamus and from 9% to 33% for the amygdala and brainstem, depending on the specific estimation method used (Rentería et al., 2014; Satizabal et al., 2019; Hibar et al., 2017). However, the possible association between the polygenic component of brain subcortical structures and response to medications in MDD has not been investigated to the best of our knowledge. To contribute to fill this gap, we investigated the relationship between the PGSs for seven subcortical brain structure volumes (i.e., nucleus accumbens, amygdala, caudate nucleus, globus pallidus, putamen, thalamus, and hippocampus) and non-response and non-remission, across five clinical cohorts of patients with MDD. We hypothesised that the PGSs of these traits could be associated with treatment efficacy and could contribute to the future development of models able to aid the early identification of non-responders and non-remitters. This could have clinical implications, e.g., these individuals could benefit from early intensive pharmacological treatments or medications potentiated with non-pharmacological interventions for MDD, rather than following the traditional stepwise trial-and-error approach.

## 2. Material and methods

### 2.1. Target samples

#### 2.1.1. Brescia

This sample included 501 subjects with MDD (DSM-IV criteria) who were referred to the “Villa Santa Chiara” Psychiatric Hospital in Verona, Italy. The diagnosis was confirmed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Participants who had other primary neuropsychiatric disorders, including intellectual disabilities, substance/alcohol abuse or dependence, dementias, or comorbid eating disorders, were excluded. The severity of symptoms was evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS). Response was defined as  $\geq 50\%$  improvement in symptom severity during the

current pharmacological treatment. Non-responders were patients who did not respond to at least one pharmacological treatment and were categorised as Stage I-III according to the Thase and Rush staging method (Thase and Rush, 1997). Genome-wide genotyping was conducted using either the Infinium PsychArray-24 BeadChip or the Infinium Multi-Ethnic Genotyping Array ( $N = 215$  and  $286$ , respectively, denominated Brescia sample 1 and Brescia sample 2 in the supplementary materials). Further details are available elsewhere (Minelli et al., 2015).

### 2.1.2. European Group for the Study of Resistant Depression

A total of 1410 participants were recruited by the European Group for the Study of Resistant Depression (GSRD) as part of a multicentric cross-sectional study. Patients had a diagnosis of MDD (DSM-IV-TR criteria), according to the Mini International Neuropsychiatric Interview (MINI), and they were treated with a medication for depression for  $\geq 4$  weeks. The main exclusion criterion was another primary psychiatric disorder in the six months before enrolment. Depression severity was assessed using the MADRS at study entry and at the beginning of current episode (retrospectively, from anamnestic information and medical records). Treatment response was defined as a  $\geq 50\%$  reduction in the MADRS total score compared to the beginning of the current episode, after treatment with a medication for depression for  $\geq 4$  weeks. Non-responders were patients who did not respond to one or more pharmacological treatments during the current depressive episode. Remission was determined based on a current MADRS  $\leq 10$  after treatment with a medication for depression for  $\geq 4$  weeks. Genome-wide genotyping was performed with Infinium PsychArray-24 BeadChip. Additional information on this study is available elsewhere (Fanelli et al., 2021, 2022b; Dold et al., 2022).

### 2.1.3. Münster

This naturalistic study involved 621 individuals with MDD (DSM-IV criteria), confirmed using the SCID-I (Baune et al., 2010), recruited at the Department of Psychiatry, University of Münster, Germany. Patients with current alcohol/drug dependence or other primary neuropsychiatric disorders were excluded. Treatment response and remission were evaluated after six weeks of treatment, using the 21-item Hamilton Depression Rating Scale (HAMD<sub>21</sub>) ( $\geq 50\%$  improvement from baseline and HAMD<sub>21</sub>  $\leq 7$ , respectively). Genome-wide genotyping was conducted using the Infinium PsychArray-24 BeadChip.

### 2.1.4. Sequenced treatment alternatives to relieve depression

The Sequenced treatment alternatives to relieve depression (STAR\*D) study evaluated the effectiveness and tolerability of different medications in treating moderate-severe MDD (DSM-IV-TR) in primary care or psychiatric outpatient clinics. Patients with any other primary psychiatric diagnosis were excluded. The study initially involved treatment with citalopram for 12 weeks, and only this phase of the study was considered for the present analyses. Symptom severity was assessed using the Quick Inventory of Depressive Symptomatology Clinician-rated scale (QIDS-C<sub>16</sub>). Response was defined as a  $\geq 50\%$  decrease in symptom severity after 12 weeks of treatment with citalopram, and remission as QIDS-C<sub>16</sub>  $\leq 5$  at week 12. A total of 1948 participants were genome-wide genotyped using the Affymetrix GeneChip Human Mapping 500 K Array Set or Affymetrix Genome-Wide Human SNP Array 5.0. Further details of the study are available elsewhere (Howland, 2008).

### 2.1.5. Tartu

This sample included 83 outpatients with MDD (DSM-IV criteria) recruited at the Psychiatric Clinic of the University Hospital of Tartu, Estonia. The diagnosis was verified using medical records and MINI 5.0.0. Patients with current suicide risk or another primary neuropsychiatric disorder were excluded. Treatment response was defined as a  $\geq 50\%$  decrease in MADRS scores from baseline, while remission as MADRS  $\leq 10$  at week six. The Illumina 370CNV array was used for

genome-wide genotyping. Additional details are available elsewhere (Tammiste et al., 2013).

## 2.2. Quality control of genotypes in the target datasets

Each of the five target samples underwent quality control (QC) and population principal component analysis (PCA) through the Ricopili pipeline (Lam et al., 2020). SNPs were filtered retaining those with call rate  $\geq 0.95$ , missing difference between cases-controls  $\leq 0.02$ , minor allele frequency (MAF)  $\geq 0.01$ , and Hardy-Weinberg equilibrium  $p$ -value  $\geq 1e^{-6}$ . Individuals were retained if they had an autosomal heterozygosity deviation not outside of  $\pm 0.2$ , call rate  $\geq 0.98$ , and no genetic/phenotypic sex mismatch.

To assess between-subjects relatedness and population stratification, linkage disequilibrium-pruned data ( $R^2 < 0.2$ ) were used to identify all pairs of individuals with identity-by-descent proportion  $> 0.2$ , and one individual from each pair was removed. Population stratification was determined using PCA (Eigenstrat); population outliers were removed according to the mean  $\pm 6$  standard deviations of the first 20 principal components (PCs). Only individuals of European ancestry were retained based on self-report/anamnestic information and inspection of PCA plots (Lam et al., 2020).

Genotype imputation was carried out on the Michigan Imputation Server (Das et al., 2016) using Minimac4 and the Haplotype Reference Consortium (HRC) r1.1 2016 (GRCh37/hg19).

Post-imputation QC was performed by filtering out variants having a poor imputation quality score ( $R^2 < 0.3$ ) and MAF  $< 0.05$ .

## 2.3. Statistical analyses

Summary statistics of the largest available GWASs on subcortical brain structure volumes were used as base datasets (Satizabal et al., 2019; Hibar et al., 2017). We computed PGSs using PRS-CS-auto, a Bayesian method that places continuous shrinkage priors on SNP effect sizes and obviates the need to select any *a priori* GWAS  $P$ -threshold for SNP inclusion (Ge et al., 2019).

Treatment outcomes were non-response and non-remission, defined in accordance with the standard definitions and scales used in each study (paragraph 2.1 and Table 1); outcomes were used as binary dependent variables in multiple logistic regression models. The independent variables were each PGS (standardised to have mean = 0, SD = 1), age, sex, baseline symptom severity (for non-remission), relevant population principal components, and recruitment sites, as performed in a previous study (Fanelli et al., 2022b). The analyses were conducted using R v4.0.2. The variance in the outcomes explained by each PGS was estimated as the difference between the Nagelkerke's pseudo  $R^2$  of the full models and those including covariates only, in each cohort separately (Oliva et al., 2023).

The results obtained in each sample were meta-analysed using the R metafor package (Viechtbauer, 2010), within a random-effects model, using the restricted maximum-likelihood estimator (Harville, 1977). Analyses of heterogeneity were performed using the Cochran's Q test (Cochran, 1950), and  $I^2$  statistic (0% indicates no heterogeneity, and 25%, 50%, and 75% define the thresholds for low, moderate, and high, respectively) (Higgins et al., 2019). Leave-one-out sensitivity analyses were conducted as a systematic approach to assess the impact of each individual study on the overall results. This was achieved by systematically excluding one study at a time from the analyses, allowing for a thorough exploration of how each study's inclusion or exclusion influences the robustness and stability of the findings (Viechtbauer and Cheung, 2010).

The Bonferroni correction was applied considering the seven base phenotypes analysed ( $\alpha = 0.05/7 = 0.007$ ).

We estimated statistical power using the AVENGEME R package (Palla and Dudbridge, 2015). Assuming a covariance of 50% between the base and target phenotypes, all the analysed PGSs showed adequate

**Table 1**

Main clinical-demographic characteristics of the target samples included in the meta-analysis. For further information and descriptive statistics see a previously published work (Fanelli et al., 2022).

Target sample	N total	Definition of treatment outcomes	Distribution of the outcome	Time point of outcome evaluation	Age (mean $\pm$ SD)	Proportion of males
Brescia	453	Response: $\geq 50\%$ reduction in symptom severity vs baseline (MADRS scale)	Response/non-response = 72/381	$\geq 4$ weeks	Responders: 53.92 $\pm$ 13.27 Non-responders: 56.74 $\pm$ 13.70	Responders: 0.26 Non-responders: 0.33
GSRD	1149	Response: $\geq 50\%$ reduction in symptom severity vs baseline (MADRS scale)	Response/non-response = 279/870	$\geq 4$ weeks	Responders: 51.57 $\pm$ 15.70 Non-responders: 51.93 $\pm$ 13.51	Responders: 0.35 Non-responders: 0.33
		Remission: MADRS $\leq 10$	Remission/non-remission = 189/960		Remitters: 52.238 $\pm$ 15.48 Non-remitters: 51.761 $\pm$ 13.79	Remitters: 0.32 Non-remitters: 0.34
Münster	557	Response: $\geq 50\%$ reduction in symptom severity vs baseline (HAMD <sub>21</sub> scale)	Response/non-response = 351/206	6 weeks	Responders: 49.63 $\pm$ 15.11 Non-responders: 49.68 $\pm$ 16.07	Responders: 0.58 Non-responders: 0.57
		Remission: HAMD <sub>21</sub> $\leq 7$	Remission/non-remission = 249/308		Remitters: 49.01 $\pm$ 15.02 Non-remitters: 50.16 $\pm$ 15.81	Remitters: 0.57 Non-remitters: 0.58
STAR*D	1400	Response: $\geq 50\%$ reduction in symptom severity vs baseline (QIDS-C <sub>16</sub> scale)	Response/non-response = 795/605	12 weeks	Responders: 42.28 $\pm$ 13.48 Non-responders: 43.73 $\pm$ 13.46	Responders: 0.39 Non-responders: 0.42
		Remission: QIDS-C <sub>16</sub> $\leq 5$	Remission/non-remission = 597/803		Remitters: 42.02 $\pm$ 13.85 Non-remitters: 43.56 $\pm$ 13.18	Remitters: 0.39 Non-remitters: 0.41
Tartu	78	Response: $\geq 50\%$ reduction in symptom severity vs baseline (MADRS scale)	Response/non-response = 53/25	6 weeks	Responders: 30.45 $\pm$ 12.23 Non-responders: 31.92 $\pm$ 10.46	Responders: 0.42 Non-responders: 0.20
		Remission: MADRS $\leq 10$	Remission/non-remission = 50/28		Remitters: 29.86 $\pm$ 11.99 Non-remitters: 32.82 $\pm$ 10.95	Remitters: 0.40 Non-remitters: 0.25

**Abbreviations:** GSRD, European Group for the Study of Resistant Depression; HAMD<sub>21</sub>, 21-item Hamilton Depression Rating Scale score; MADRS, Montgomery-Asberg Depression Rating Scale score; N, sample size; QIDS-C<sub>16</sub>, Quick rated scale score; SD, standard deviations; STAR\*D, Sequenced Treatment Alternatives to Relieve Depression.

power ( $\geq 90\%$ ) for both target phenotypes. The power decreased to a range of 24%–48% when the covariance was set to 25%. Details on the power analysis are provided in the Supplementary materials.

### 3. Results

After QC, a total of 3637 patients with MDD were included in the analyses (Brescia  $n = 453$ ; GSRD  $n = 1149$ ; Munster  $n = 557$ ; STAR\*D  $n = 1400$ ; Tartu  $n = 78$ ), as reported in a previous publication (Fanelli et al., 2022b). The clinical-demographic characteristics of each sample

**Table 2**

Results of the meta-analyses.

PGS	Outcome	OR (95% CI)	Beta	SE	p	Qp	I <sup>2</sup>	range pseudo-R <sup>2</sup> (%)
Nucleus accumbens	non-response	0.99 (0.92–1.07)	−0.004	0.039	0.911	0.44	0	0.004–2.3
	non-remission	1.03 (0.95–1.12)	0.029	0.042	0.493	0.55	0.01	0.01–2.1
Amygdala	non-response	1.06 (0.98–1.14)	0.055	0.039	0.162	0.51	0	0.001–1.6
	non-remission	1.05 (0.95–1.17)	0.052	0.054	0.34	0.26	26.26	0.001–1.4
Caudate nucleus	non-response	1.01 (0.93–1.11)	0.012	0.045	0.781	0.20	12.06	0.005–2.4
	non-remission	1.09 (1.01–1.19)	0.09	0.043	0.036	0.45	0	0.01–0.6
Hippocampus	non-response	1.02 (0.95–1.11)	0.022	0.04	0.578	0.63	0	0.005–2.2
	non-remission	1.01 (0.92–1.09)	0.005	0.043	0.901	0.85	0	0.009–0.6
Globus pallidus	non-response	1.06 (0.92–1.22)	0.057	0.071	0.427	0.05	55.33	0.01–5.7
	non-remission	1.03 (0.89–1.18)	0.027	0.071	0.705	0.07	52.09	0.1–3.7
Putamen	non-response	0.99 (0.92–1.08)	−0.001	0.042	0.989	0.56	0	0.1–1.6
	non-remission	1.01 (0.92–1.09)	0.003	0.046	0.955	0.46	0.01	9.64e-05 – 1.9
Thalamus	non-response	0.94 (0.86–1.02)	−0.064	0.043	0.138	0.21	9.36	0.005–3.6
	non-remission	0.91 (0.81–1.04)	−0.092	0.066	0.165	0.18	46.45	0.001–1.4

**Abbreviations:** Beta, regression coefficient; SE, standard error; CI, confidence interval; I<sup>2</sup>, Higgin and Thompson's I<sup>2</sup> estimating how much of the total variability in the effect size estimates can be attributed to heterogeneity among the true effects; OR, odds ratio; Qp, p-value for the Cochran's Q-test of (residual) heterogeneity; PGS, polygenic score; range pseudo-R<sup>2</sup>, Nagelkerke's R<sup>2</sup>s (range of values, as pseudo-R<sup>2</sup> was calculated in each cohort, expressed as percentage). Bonferroni corrected p-value was 0.007.



are reported in Table 1 and in a previous work (Fanelli et al., 2022b). In the meta-analyses, no association survived after the Bonferroni correction (Table 2). The top result was found for the association between the caudate nucleus PGS and non-remission (OR = 1.09, 95% CI = 1.01–1.19, p = 0.036, range pseudo-R<sup>2</sup> = 0.01–0.6%), with no evidence of heterogeneity (Table 2); a forest plot is depicted in Fig. 1. Leave-one-out sensitivity analyses conducted for this association identified a significant influence of GSRD and STAR\*D samples on the overall result; removing each one of these samples from the meta-analysis showed indeed an impact on the results (p = 0.230 and p = 0.351, respectively). The results of regression analyses in each sample and of the other leave-one-out sensitivity analyses are provided in the Supplementary materials. We briefly mention that all other leave-one-out sensitivity analyses showed p-values >0.05, except for the amygdala PGS when considering both non-response and non-remission after excluding the Münster sample (p = 0.048 and 0.041, respectively), and thalamus PGS and remission when excluding STAR\*D (p = 0.009).

4. Discussion

In the present meta-analysis, we investigated whether the PGSs for seven brain subcortical volumes were associated with non-response or non-remission in a total sample of 3637 patients with MDD. No association survived after Bonferroni correction, but our top finding suggests possible genetic sharing between the PGS for caudate volume and non-remission, after adjusting for possible confounders. Previous evidence of associations between hippocampal volume, MDD and response to pharmacological treatment were not corroborated by our study (Dusi et al., 2015; Chi et al., 2015). The caudate nucleus is important for executive function, which includes the regulation of affective states, hence the interest in this structure in the study of MDD (Gotlib and Joormann, 2010). A previous meta-analysis of neuroimaging studies reported significant volume reductions in the caudate nucleus in patients with depression compared to healthy controls (Bora et al., 2012), which were attributed to decreases in both grey matter volume (Kim et al., 2008) and neuronal density (Khundakar et al., 2011). Greater caudate reduction was associated with more severe depression (Butters et al., 2009). Preliminary evidence from

small samples indicated that caudate nuclei do not differ between non-responders and responders to pharmacological treatment, although possible sex effects were suggested (Pillay et al., 1998). However, fronto-striatal atrophy, characterized by a reduction in caudate volume, was observed in patients with treatment-resistant depression when compared to patients with depression in remission (Willner et al., 2013). Additionally, reduced bilateral caudate volume was observed in patients with MDD and elevated anhedonic symptoms (Pizzagalli et al., 2009), which are also associated with treatment non-response (Perlman et al., 2019). The caudate nucleus has a key role in the reward system (Doi et al., 2020), and anhedonia is believed to result from the dysfunction of reward and motivational dopaminergic neural circuits (Satterthwaite et al., 2015). A PET study investigated dopaminergic receptor availability in the striatum, including the caudate nucleus, in individuals with MDD. Patients, particularly non-remitters, demonstrated higher dopaminergic receptor availability compared to healthy controls, suggesting a significant role of dopaminergic dysfunction in response to first-line treatments for depression (Peciña et al., 2017). Although our findings are apparently not in line with some previous evidence from brain imaging studies, a recent work showed a positive genetic correlation between MDD and caudate volume (Werme et al., 2023), therefore genetic factors associated with higher volume of this structure may overlap with both MDD and lack of remission to treatment. Environmental factors interact with genetic variables in determining brain volumes, therefore future studies should also consider the modulating effects of the environment on genetic factors. Taken collectively, these findings suggest the potential relevance of augmentation therapy employing drugs that target the dopaminergic system for MDD (Corponi et al., 2019). However, we underline that our result did not survive multiple-testing correction, and it was influenced by the two largest samples in the meta-analysis (i.e., GSRD and STAR\*D), suggesting inadequate statistical power for a robust and stable finding. The contribution of the GSRD sample to this result can also be influenced by the higher prevalence of non-remission than all the other samples included in the analysis. Despite these findings did not emerge in the main analysis and did not reach the Bonferroni corrected significance threshold, we briefly mention that leave-one-out analyses suggested a possible influence of




Fig. 1. Forest plot showing the association between the polygenic score for caudate volume and non-remission. Abbreviations: GSRD, European Group for the Study of Resistant Depression; CI, confidence interval; df, degree of freedom; I<sup>2</sup>, Higgin and Thompson's I<sup>2</sup> estimating how much of the total variability in the effect size estimates can be attributed to heterogeneity among the true effects; OR, odds ratio; p, p-value for the Cochran's Q-test of (residual) heterogeneity; PGS, polygenic score; Q, Cochran's Q-test statistic; RE, random effect model; STAR\*D, Sequenced Treatment Alternatives to Relieve Depression; τ<sup>2</sup>, between-study variance.

the amygdala PGS on both non-response and non-remission, as well as an association between the thalamus PGS and remission.

The results referred to the amygdala PGS and both non-remission/non-response were found after the exclusion of the Münster sample, which was the only one that used the HAMD<sub>21</sub> for the assessment of response and remission, a scale that was reported to show low sensibility to change (Jakobsen et al., 2020), with possible implications in terms of comparability with the other cohorts. The amygdala has long been an interesting region in neurobiological studies of depressive-anxious disorders, owing to its relevant role in emotional processing and regulation (Simić et al., 2021; Kirstein et al., 2023). A previous neuroimaging meta-analysis found no difference in the amygdala volume between people with depression and healthy controls, despite including only patients taking medications may have influenced the result (Hamilton et al., 2008). Neuroimaging functional studies showed instead associations suggesting a link between non-remission and lower connectivity in white matter pathways to the amygdala (Chi et al., 2015) and decreased amygdala function (Rajeev and Jonathan, 2012; Kemp et al., 2008).

The result referred to the thalamus PGS and remission was found after excluding STAR\*D, which was the largest sample in this meta-analysis. We therefore suggest that this could have affected substantially the result, in addition to heterogeneity factors linked to STAR\*D's characteristics (e.g., participants were largely recruited in primary care settings, had long duration of illness, and significant medical and psychiatric comorbidities (Laje et al., 2009)). Despite the role of the thalamus in the regulation of emotion, memory, and arousal (Taber et al., 2004), there is no consistent evidence supporting structural changes of the thalamus in MDD. A meta-analysis of structural studies, including both treated and untreated patients with MDD, showed smaller grey matter volume in patients vs healthy controls (Du et al., 2012), while a later meta-analysis that focused only on untreated MDD patients revealed a result in the opposite direction (Peng et al., 2016). Therefore, medication use and potentially other variables may have an impact on the grey matter structure of the thalamus and explain these inconsistent findings. Our result suggests that common genetic variation could be one of these variables, even if it is discussed only for completeness and to provide elements for future hypotheses, being found only in the leave-one out sensitivity analyses and not significant after Bonferroni correction.

The strengths and limitations of this study should be considered. We used a standardised genetic QC procedure on the target datasets in line with current standards, we applied a strict correction for multiple testing, we performed a random-effect meta-analysis of our results across the five target samples, and we included socio-demographic and clinical variables as potential confounders in the regression models. Potential limitations included the heterogeneity in the time points used for the assessment of efficacy outcomes (i.e., six weeks, at least four weeks, or 12 weeks, depending on the cohort), which could not be assessed in a sensitivity analysis as each cohort used a different time point. However, it is important to note that all studies considered treatment efficacy in the short term and after a period of treatment of at least four weeks, which is considered adequate to measure medication therapeutic effects (Fabbri et al., 2021b). Other heterogeneity factors across studies were the scales used to measure depressive symptoms and treatment, as all studies had a naturalistic design (i.e., pharmacological treatment was prescribed according to the principles of best medical practice), except STAR\*D (all patients were treated with citalopram). Future studies should aim to obtain a better harmonization of efficacy outcomes (Sforzini et al., 2022). Additionally, the disparity in statistical power across different genetic covariance estimates suggests a probable lack of sufficient power, emphasising the necessity of conducting studies with larger sample sizes. This might explain the fact that no association survived after multiple testing correction and the proportion of phenotypic variance explained by PGSs was limited. Finally, environmental factors should be considered in conjunction with genetic variation by studies evaluating brain imaging measures. For example, childhood

trauma could act as a mediator between alterations in grey matter volumes (Kang et al., 2023) and treatment outcomes (Oliva et al., 2022; Fares-Otero et al., 2023).

In conclusion, our study found a potential association between the PGS for caudate nucleus volume and non-remission, suggesting shared underlying genetic factors. However, the examined PGSs were not able to predict treatment response or remission after multiple-testing correction. In the future, it will be crucial to include larger sample sizes, as our power analysis suggested a probable insufficient power despite our meta-analytical approach. Collaborative efforts through consortia and networks could enhance the availability of further samples and ideally of harmonised phenotypic definitions, enabling the discovery of genetic associations.

## Statement of ethics

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All participants were included after obtaining their written informed consent. Brescia study protocol was approved by the Ethics Committee of the province of Verona, Italy; the European Group for the Study of Resistant Depression (GSRD) study protocol was approved by the Ethics Committee of the coordinating center at Hôpital Erasme, Cliniques universitaires de Bruxelles (Université Libre de Bruxelles), Belgium, and the local ethical committees of all the other nine participating centres; the Münster study protocol was approved by the ethical board of the University of Münster, Germany; the Tartu study protocol was approved by the Human Studies Ethics Committee of the University of Tartu and State Agency of Medicines; the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) study protocol received ethics approval from 14 participating institutional review boards, a National Coordinating Center, a Data Coordinating Center, and the Data Safety and Monitoring Board at the National Institute of Mental Health (NIMH), Bethesda, Maryland, US.

## Authors statement contributors

Vincenzo Oliva contributed to the conceptualisation of the study, performed the analyses, interpreted the results, and wrote the first draft of the manuscript. Alfonso Martone contributed to data analyses. Giuseppe Fanelli conceptualised the study, performed quality control and imputation of individual genotype data in each target sample, and reviewed the first draft of the manuscript. Alessandro Serretti and Chiara Fabbri conceptualised the study, helped with the interpretation of the results, reviewed the first draft of the manuscript. Chiara Fabbri created the polygenic scores and supervised the process leading to the final version of the work. The other authors contributed to data collection, data preparation and/or provided comments, suggestions, and revisions, leading to the final version of the paper. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

## Declaration of interest

B.T. Baune: Advisory Board - Lundbeck, Janssen-Cilag; Consultant - National Health and Medical Research Council, Australia; Grant/Research Support - AstraZeneca, Fay Fuller Foundation, James & Diana Ramsay Foundation, National Health and Medical Research Council, Australia, German Research Council (DFG), Sanofi, Lundbeck; Honoraria - AstraZeneca, Bristol-Myers Squibb, Lundbeck, Pfizer, Servier Laboratories, Wyeth Pharmaceuticals, Takeda, Janssen, LivaNova PLC. K. Domschke has been a member of the Steering Committee Neurosciences, Janssen Pharmaceuticals, and has received speaker's honoraria

from Janssen Pharmaceuticals. Inc. P. Ferentinos received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, Boehringer-Ingelheim, Janssen, Medochemie, Vianex, and Servier. S. In the past 3 years Dr Kasper served as a consultant or on advisory boards for Angelini, Biogen, Boehringer, Esai, Janssen, IQVIA, Mylan, Recordati, Rovi, Sage and Schwabe; and he has served on speakers bureaus for Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Recordati, Schwabe, Servier, Sothema, and Sun Pharma. E. Maron has received grant/research support from Lundbeck, Janssen, Sanofi and GlaxoSmithKline. S. Mendlewicz is a member of the board of the Lundbeck International Neuroscience Foundation and of the advisory board of Servier. S. Montgomery has been a consultant or served on advisory boards for Lundbeck. A. Serretti is or has been a consultant/speaker for Abbott, Abbvie, Angelini, AstraZeneca, Clinical Data, Boehringer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, and Servier. D. Souery has received grant/research support from GlaxoSmithKline and Lundbeck, and he has served as a consultant or on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, and Lundbeck. J. Zohar has received grant/research support from Lundbeck, Servier, and Pfizer; he has served as a consultant on the advisory boards for Servier, Pfizer, Solvay, and Actelion; and he has served on speakers' bureaus for Lundbeck, GSK, Jazz, and Solvay. C. Fabbri was a speaker for Janssen. The other authors declare no conflict of interest.

### Role of the funding source

The European Group for the Study of Resistant Depression (GSRD) was supported by an unrestricted grant from Lundbeck that had no further role in the study design, data collection, analysis, and interpretation, as well as in writing and submitting of the manuscript for publication.

Bernhard T Baune, Chiara Fabbri, Alessandro Serretti, Vincenzo Oliva, Alessio Squassina, Claudia Pisanu, and Alessandra Minelli received support from Psych-STRATA, a project funded from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101057454. Massimo Gennarelli received support by the Italian Ministry of Health under Grant (Ricerca Corrente 2023).

### Data availability

Access to the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) data is granted to Principal Investigators after approval of a research proposal to the National Institute of Mental Health (NIMH) via the NIMH Repository & Genomics Resource (NRGR) (<https://www.nimhgenetics.org>).

### Declaration of Generative AI and AI- assisted technologies in the writing process

None.

### Acknowledgements

The European College of Neuropsychopharmacology (ECNP) Pharmacogenomics and Transcriptomics Network contributed to this manuscript by sharing sample data, as well as providing comments and critical review to the manuscript.

We thank the US National Institute of Mental Health (NIMH) for providing access to data on the STAR\*D sample. We also thank the authors of previous publications in this dataset, and foremost, we thank the patients and their families who agreed to be enrolled in the study. Data were obtained from the limited access dataset distributed from the NIH-supported STAR\*D (NIMH Contract No. N01MH90003, [ClinicalTrials.gov](https://clinicaltrials.gov) identifier is NCT00021528).

[ClinicalTrials.gov](https://clinicaltrials.gov) identifier is NCT00021528).

We thank the European Group for the Study of Resistant Depression (GSRD) for providing access to the dataset they collected, as well as the researchers of the consortia that provided the GWAS summary statistics used in our analyses and the participants of the cohorts to which they refer.

### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nsa.2024.103937>.

### References

- Amare, A.T., Schubert, K.O., Tekola-Ayele, F., Hsu, Y.H., Sangkuhl, K., Jenkins, G., et al., 2018. Association of the polygenic scores for personality traits and response to selective Serotonin Reuptake inhibitors in patients with major depressive disorder. *Front. Psychiatr.* 9, 65. <https://doi.org/10.3389/fpsyt.2018.00065>.
- Amare, A.T., Schubert, K.O., Tekola-Ayele, F., Hsu, Y.-H., Sangkuhl, K., Jenkins, G., et al., 2019. The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. *J. Neural. Transm.* 126, 35–45.
- Baune, B.T., Dannlowski, U., Domschke, K., Janssen, D.G., Jordan, M.A., Ohrmann, P., et al., 2010. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. *Biol. Psychiatr.* 67 (6), 543–549.
- Bora, E., Harrison, B.J., Davey, C.G., Yücel, M., Pantelis, C., 2012. Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder. *Psychol. Med.* 42 (4), 671–681. <https://doi.org/10.1017/s0033291711001668>.
- Butters, M.A., Aizenstein, H.J., Hayashi, K.M., Meltzer, C.C., Seaman, J., Reynolds, C.F., et al., 2009. Three-dimensional surface mapping of the caudate nucleus in late-life depression. *Am. J. Geriatr. Psychiatr.* 17 (1), 4–12. <https://doi.org/10.1097/JGP.0b013e31816ff72b>.
- Chi, K.F., Korgaonkar, M., Grieve, S.M., 2015. Imaging predictors of remission to antidepressant medications in major depressive disorder. *J. Affect. Disord.* 186, 134–144. <https://doi.org/10.1016/j.jad.2015.07.002>.
- Choi, S.W., O'Reilly, P.F., 2019. PRSice-2: polygenic Risk Score software for biobank-scale data. *GigaScience* 8 (7), giz082.
- Cochran, W.G., 1950. The comparison of percentages in matched samples. *Biometrika* 37 (3/4), 256–266.
- Corponi, F., Fabbri, C., Bitter, I., Montgomery, S., Vieta, E., Kasper, S., et al., 2019. Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. *Eur. Neuropsychopharmacol.* 29 (9), 971–985.
- Craig, J.E., Han, X., Qassim, A., Hassall, M., Cooke Bailey, J.N., Kinzy, T.G., et al., 2020. Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. *Nat. Genet.* 52 (2), 160–166. <https://doi.org/10.1038/s41588-019-0556-y>.
- Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., et al., 2016. Next-generation genotype imputation service and methods. *Nat. Genet.* 48 (10), 1284–1287.
- De Carlo, V., Calati, R., Serretti, A., 2016. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: a systematic review. *Psychiatr. Res.* 240, 421–430. <https://doi.org/10.1016/j.psychres.2016.04.034>.
- Doi, T., Fan, Y., Gold, J.I., Ding, L., 2020. The caudate nucleus contributes causally to decisions that balance reward and uncertain visual information. *eLife* 9, e56694. <https://doi.org/10.7554/eLife.56694>.
- Dold, M., Bartova, L., Fugger, G., Mitschke, M.M., Fabbri, C., Serretti, A., et al., 2022. Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. *J. Affect. Disord.* 296, 485–492. <https://doi.org/10.1016/j.jad.2021.09.063>.
- Domschke, K., Deckert, J., Arolt, V., Baune, B.T., 2010. Anxious versus non-anxious depression: difference in treatment outcome. *J. Psychopharmacol.* 24 (4), 621–622. <https://doi.org/10.1177/0269881108097723>.
- Du, M.Y., Wu, Q.Z., Yue, Q., Li, J., Liao, Y., Kuang, W.H., et al., 2012. Voxelwise meta-analysis of gray matter reduction in major depressive disorder. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 36 (1), 11–16. <https://doi.org/10.1016/j.pnpbp.2011.09.014>.
- Dusi, N., Barlati, S., Vita, A., Brambilla, P., 2015. Brain structural effects of antidepressant treatment in major depression. *Curr. Neuropsychopharmacol.* 13 (4), 458–465.
- Fabbri, C., Montgomery, S., Lewis, C.M., Serretti, A., 2020. Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. *Int. Clin. Psychopharmacol.* 35 (5).
- Fabbri, C., Hagenaars, S.P., John, C., Williams, A.T., Shrine, N., Moles, L., et al., 2021a. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. *Mol. Psychiatr.* 26 (7), 3363–3373.
- Fabbri, C., Hagenaars, S.P., John, C., Williams, A.T., Shrine, N., Moles, L., et al., 2021b. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. *Mol. Psychiatr.* 26 (7), 3363–3373. <https://doi.org/10.1038/s41380-021-01062-9>.



- Fanelli, G., Benedetti, F., Kasper, S., Zohar, J., Souery, D., Montgomery, S., et al., 2021. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. *Prog. Neuro Psychopharmacol. Biol. Psychiatr.* 108, 110170 <https://doi.org/10.1016/j.pnpbp.2020.110170>.
- Fanelli, G., Sokolowski, M., Wasserman, D., Research ECoNNoS, Prevention, Kasper, S., et al., 2022a. Polygenic risk scores for neuropsychiatric, inflammatory, and cardiometabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation. *Am. J. Med. Genet. Part B: Neuropsychiatric Genet.* 189 (3–4), 74–85.
- Fanelli, G., Domschke, K., Minelli, A., Gennarelli, M., Martini, P., Bortolomasi, M., et al., 2022b. A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. *Eur. Neuropsychopharmacol.* 55, 86–95.
- Fares-Otero, N.E., De Prisco, M., Oliva, V., Radua, J., Halligan, S.L., Vieta, E., et al., 2023. Association between childhood maltreatment and social functioning in individuals with affective disorders: a systematic review and meta-analysis. *Acta Psychiatr. Scand.* 148 (2), 142–164. <https://doi.org/10.1111/acps.13557>.
- Fettes, P., Schulze, L., Downar, J., 2017. Cortico-striatal-thalamic loop circuits of the orbitofrontal cortex: promising therapeutic targets in psychiatric illness. *Front. Syst. Neurosci.* 11, 25.
- Fusar-Poli, P., Manchia, M., Koutsouleris, N., Leslie, D., Woopen, C., Calkins, M.E., et al., 2022. Ethical considerations for precision psychiatry: a roadmap for research and clinical practice. *Eur. Neuropsychopharmacol.* 63, 17–34. <https://doi.org/10.1016/j.euroneuro.2022.08.001>.
- Ge, T., Chen, C.Y., Ni, Y., Feng, Y.A., Smoller, J.W., 2019. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat. Commun.* 10 (1), 1776. <https://doi.org/10.1038/s41467-019-09718-5>.
- Gotlib, I.H., Joormann, J., 2010. Cognition and depression: current status and future directions. *Annu. Rev. Clin. Psychol.* 6, 285–312. <https://doi.org/10.1146/annurev.clinpsy.121208.131305>.
- Hamilton, J.P., Siemer, M., Gotlib, I.H., 2008. Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. *Mol. Psychiatr.* 13 (11), 993–1000.
- Harville, D.A., 1977. Maximum likelihood approaches to variance component estimation and to related problems. *J. Am. Stat. Assoc.* 72 (358), 320–338.
- Hibar, D.P., Adams, H.H., Jahanshad, N., Chauhan, G., Stein, J.L., Hofer, E., et al., 2017. Novel genetic loci associated with hippocampal volume. *Nat. Commun.* 8 (1), 13624.
- Higgins, J.P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., et al., 2019. *Cochrane Handbook for Systematic Reviews of Interventions*. John Wiley & Sons.
- Howland, R.H., 2008. Sequenced treatment alternatives to relieve depression (STAR\*D)—Part 2: study outcomes. *J. Psychosoc. Nurs. Ment. Health Serv.* 46 (10), 21–24.
- Jakobsen, J.C., Gluud, C., Kirsch, I., 2020. Should antidepressants be used for major depressive disorder? *BMJ Evid.-Based Med.* 25 (4), 130.
- Kang, W., Kang, Y., Kim, A., Kim, H., Han, K.-M., Ham, B.-J., 2023. Gray and white matter abnormalities in major depressive disorder patients and its associations with childhood adversity. *J. Affect. Disord.* 330, 16–23. <https://doi.org/10.1016/j.jad.2023.02.145>.
- Kautzky, A., Dold, M., Bartova, L., Spies, M., Vanicek, T., Souery, D., et al., 2017. Refining prediction in treatment-resistant depression: results of machine learning analyses in the TRD III sample. *J. Clin. Psychiatr.* 79 (1), 14989.
- Kemp, A.H., Gordon, E., Rush, A.J., Williams, L.M., 2008. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. *CNS Spectr.* 13 (12), 1066–1086.
- Kendrick, T., Pilling, S., Mavranzeouli, I., Megnin-Viggars, O., Ruane, C., Eadon, H., et al., 2022. Management of depression in adults: summary of updated NICE guidance. *BMJ* 378, o1557. <https://doi.org/10.1136/bmj.o1557>.
- Khundakar, A., Morris, C., Oakley, A., Thomas, A.J., 2011. Morphometric analysis of neuronal and glial cell pathology in the caudate nucleus in late-life depression. *Am. J. Geriatr. Psychiatr.* 19 (2), 132–141. <https://doi.org/10.1097/JGP.0b013e3181df4642>.
- Kim, M.J., Hamilton, J.P., Gotlib, I.H., 2008. Reduced caudate gray matter volume in women with major depressive disorder. *Psychiatr. Res.* 164 (2), 114–122. <https://doi.org/10.1016/j.psychres.2007.11.020>.
- Kirstein, C.F., Güntürkün, O., Ocklenburg, S., 2023. Ultra-high field imaging of the amygdala – a narrative review. *Neurosci. Biobehav. Rev.* 152, 105245 <https://doi.org/10.1016/j.neubiorev.2023.105245>.
- Kuburi, S., Di Passa, A.-M., Tassone, V.K., Mahmood, R., Lalovic, A., Ladha, K.S., et al., 2022. Neuroimaging correlates of treatment response with psychedelics in major depressive disorder: a systematic review. *Chronic Stress* 6, 24705470221115342.
- Laje, G., Perlis, R.H., Rush, A.J., McMahon, F.J., 2009. Pharmacogenetics studies in STAR\*D: strengths, limitations, and results. *Psychiatr. Serv.* 60 (11), 1446–1457. <https://doi.org/10.1176/appi.ps.60.11.1446>.
- Lam, M., Awasthi, S., Watson, H.J., Goldstein, J., Panagiotaropoulou, G., Trubetskoy, V., et al., 2020. RICOPILI: rapid imputation for COntortias PipeLine. *Bioinformatics* 36 (3), 930–933.
- Marshe, V.S., Maciukiewicz, M., Hauschild, A.-C., Islam, F., Qin, L., Tiwari, A.K., et al., 2021. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. *Transl. Psychiatry* 11 (1), 127.
- Minelli, A., Magri, C., Barbon, A., Bonvicini, C., Segala, M., Congiu, C., et al., 2015. Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. *Transl. Psychiatry* 5 (12), e687–e.
- Natarajan, P., Young, R., Stitzel, N.O., Padmanabhan, S., Baber, U., Mehran, R., et al., 2017. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. *Circulation* 135 (22), 2091–2101.
- Olgiati, P., Fanelli, G., Serretti, A., 2022. Obsessive-compulsive symptoms in major depressive disorder correlate with clinical severity and mixed features. *Int. Clin. Psychopharmacol.* 37 (4), 166–172. <https://doi.org/10.1097/yic.0000000000000396>.
- Oliva, V., Fanelli, G., Kasper, S., Zohar, J., Souery, D., Montgomery, S., et al., 2022. Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. *Int. Clin. Psychopharmacol.* 37 (2).
- Oliva, V., Fanelli, G., Kasper, S., Zohar, J., Souery, D., Montgomery, S., et al., 2023. Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns. *J. Affect. Disord.* 320, 534–543. <https://doi.org/10.1016/j.jad.2022.10.003>.
- Pain, O., Hodgson, K., Trubetskoy, V., Ripke, S., Marshe, V.S., Adams, M.J., et al., 2022. Identifying the common genetic basis of antidepressant response. *Biol. Psychiatry Global Open Sci.* 2 (2), 115–126.
- Palla, L., Dudbridge, F., 2015. A fast method that uses polygenic scores to estimate the variance explained by genome-wide marker panels and the proportion of variants affecting a trait. *Am. J. Hum. Genet.* 97 (2), 250–259.
- Peciña, M., Sikora, M., Avery, E.T., Heffernan, J., Peciña, S., Mickey, B.J., et al., 2017. Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: implications for anhedonia, anxiety and treatment response. *Eur. Neuropsychopharmacol.* 27 (10), 977–986. <https://doi.org/10.1016/j.euroneuro.2017.08.427>.
- Peng, W., Chen, Z., Yin, L., Jia, Z., Gong, Q., 2016. Essential brain structural alterations in major depressive disorder: a voxel-wise meta-analysis on first episode, medication-naïve patients. *J. Affect. Disord.* 199, 114–123.
- Perlman, K., Benrimoh, D., Israel, S., Rollins, C., Brown, E., Tunteng, J.F., et al., 2019. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. *J. Affect. Disord.* 243, 503–515. <https://doi.org/10.1016/j.jad.2018.09.067>.
- Pillay, S.S., Renshaw, P.F., Bonello, C.M., Lafer, B.C., Fava, M., Yurgelun-Todd, D., 1998. A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. *Psychiatr. Res.* 84 (2–3), 61–74. [https://doi.org/10.1016/s0925-4927\(98\)00048-1](https://doi.org/10.1016/s0925-4927(98)00048-1).
- Pizzagalli, D.A., Holmes, A.J., Dillon, D.G., Goetz, E.L., Birk, J.L., Bogdan, R., et al., 2009. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. *Am. J. Psychiatr.* 166 (6), 702–710. <https://doi.org/10.1176/appi.ajp.2008.08081201>.
- Rajeev, K., Jonathan, C., 2012. Depression: an inflammatory illness? *J. Neurol. Neurosurg. Psychiatry* 83 (5), 495. <https://doi.org/10.1136/jnnp-2011-301779>.
- Renteria, M.E., Hansell, N.K., Strike, L.T., McMahon, K.L., de Zubicaray, G.I., Hickie, I.B., et al., 2014. Genetic architecture of subcortical brain regions: common and region-specific genetic contributions. *Gene Brain Behav.* 13 (8), 821–830.
- Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., et al., 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *Am. J. Psychiatr.* 163 (11), 1905–1917. <https://doi.org/10.1176/appi.2006.163.11.1905>.
- Satizabal, C.L., Adams, H.H., Hibar, D.P., White, C.C., Knol, M.J., Stein, J.L., et al., 2019. Genetic architecture of subcortical brain structures in 38,851 individuals. *Nat. Genet.* 51 (11), 1624–1636.
- Satterthwaite, T.D., Kable, J.W., Vandekar, L., Katchmar, N., Bassett, D.S., Baldassano, C. F., et al., 2015. Common and dissociable dysfunction of the reward system in bipolar and unipolar depression. *Neuropsychopharmacology* 40 (9), 2258–2268.
- Serretti, A., 2022. Psychopharmacology: past, present and future. *Int. Clin. Psychopharmacol.* 37 (3), 82–83. <https://doi.org/10.1097/yic.0000000000000402>.
- Sforzini, L., Worrell, C., Kose, M., Anderson, I.M., Aouizerate, B., Arolt, V., et al., 2022. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. *Mol. Psychiatr.* 27 (3), 1286–1299. <https://doi.org/10.1038/s41380-021-01381-x>.
- Šimić, G., Tkalcic, M., Vukić, V., Mulc, D., Španić, E., Šagud, M., et al., 2021. Understanding emotions: origins and roles of the Amygdala. *Biomolecules* 11 (6). <https://doi.org/10.3390/biom11060823>.
- Taber, K.H., Wen, C., Khan, A., Hurley, R.A., 2004. The limbic thalamus. *J. Neuropsychiatry Clin. Neurosci.* 16 (2), 127–132.
- Tammiste, A., Jiang, T., Fischer, K., Mägi, R., Krjutskov, K., Pettai, K., et al., 2013. Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. *J. Psychopharmacol.* 27 (10), 915–920.
- Thase, M.E., Rush, A.J., 1997. When at first you don't succeed: sequential strategies for antidepressant nonresponders. *J. Clin. Psychiatr.* 58 (13), 23–29.
- van Westrhenen, R., Ingelman-Sundberg, M., 2021. Editorial: from trial and error to individualised pharmacogenomics-based pharmacotherapy in psychiatry. *Front. Pharmacol.* 12 <https://doi.org/10.3389/fphar.2021.725565>.
- Viechtbauer, W., 2010. Conducting meta-analyses in R with the metafor package. *J. Stat. Software* 36 (3), 1–48.
- Viechtbauer, W., Cheung, M.W.L., 2010. Outlier and influence diagnostics for meta-analysis. *Res. Synth. Methods* 1 (2), 112–125.
- Vos, T., Lim, S.S., Abbafati, C., Abbas, K.M., Abbasi, M., Abbasifard, M., et al., 2020. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396 (10258), 1204–1222.
- Werme, J., Tissink, E.P., Lange, S.Cd, MpvD, Heuvel, Posthuma, D., Leeuw, CAd, 2023. Local genetic correlation analysis links depression with molecular and brain imaging



endophenotypes. medRxiv. <https://doi.org/10.1101/2023.03.01.23286613>, 2023.03.01.23286613.

Willner, P., Scheel-Krüger, J., Belzung, C., 2013. The neurobiology of depression and antidepressant action. *Neurosci. Biobehav. Rev.* 37 (10 Pt 1), 2331–2371. <https://doi.org/10.1016/j.neubiorev.2012.12.007>.

Zanardi, R., Prestifilippo, D., Fabbri, C., Colombo, C., Maron, E., Serretti, A., 2021. Precision psychiatry in clinical practice. *Int. J. Psychiatr. Clin. Pract.* 25 (1), 19–27. <https://doi.org/10.1080/13651501.2020.1809680>.